ToPCaP

Irish PROgramme for Stratified ProstatE Cancer Therapy (iPROSPECT)

Irish PROgramme for Stratified ProstatE Cancer Therapy (iPROSPECT)

Currently, treatment for Metastatic Prostate Cancer is based on trial and error. In recent years, several new treatments for Metastatic Prostate Cancer have become available which have expanded the options for patients and their doctors. The challenge now lies in selecting the most appropriate treatment and determining the order in which they should be given. Not all patients respond in the same way to these treatments; therefore, it is important to find indicators or biomarkers of disease, which can predict an individual patient’s response. The aim of this research is to identify biomarkers present in blood and tissue which correlate with treatment response and which may aid future personalised treatment decisions for patients with Metastatic Prostate Cancer. The clinical study began recruiting patients in February 2015 and will be carried out in 10 hospital sites across Ireland and 1 hospital site in Sweden. iPROSPECT comprises a series of connected projects, each of which will analyse the patients’ samples throughout the course of the disease and integrate their results with the clinical information and patient-reported outcomes in order to understand and predict response to treatments. The multi-institutional programme is funded by the Irish Cancer Society in partnership with Movember.